7 Best Stocks for the Next 30 Days

Get them in a free Special Report, and get more Zacks Insights in our free e-newsletter, Profit from the Pros. Every issue includes a fresh Zacks #1 Bull Stock of the Day.

Privacy Policy
Close This Panel X
  • Latest News
  • Most Popular
View All | Scroll Down Scroll Up

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 05/17/2013

Company Name Symbol %Change
VIASAT INC VSAT
19.35%
OLD SECOND B OSBC
5.76%
GAMCO INVEST GBL
4.61%
CORNING INC GLW
4.47%
SYNCHRONOSS SNCR
4.23%

Zacks Rank #1 Strong Buys

Analyst Blog

Print
Share

Roche Teams Up With Afraxis

by Zacks Equity Research

January 30, 2013 | Comments : 0 Recommended this article: (0)

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Roche ( RHHBY ) announced that its wholly owned subsidiary, Genentech, has recently inked a global licensing agreement with Afraxis, Inc. for developing candidates for an undisclosed novel target.
The licensing agreement provides Roche with exclusive, rights to develop and commercialize Afraxis' proprietary compounds on a worldwide basis.
Afraxis is eligible for an upfront fee along with research, development and commercialization milestone payments totaling $187.5 million.
We note that Genentech is a part of the Pharmaceuticals Division of the Roche group with primary focus on oncology along with immunology, neuroscience, metabolism and infectious disease.
We note that the oncology portfolio at Roche was boosted recently when the US Food and Drug Administration (FDA) approved Avastin (bevacizumab) for a new indication in metastatic colorectal cancer (mCRC). Avastin in combination with fluoropyrimidine-based irinotecan or oxaliplatin chemotherapy can be used for treating patients suffering from mCRC.
The new indication now allows patients suffering from mCRC who were initially treated with Avastin along with an irinotecan or oxaliplatin containing chemotherapy can now continue receiving Avastin plus a different irinotecan or oxaliplatin containing chemotherapy, after the cancer worsens (second-line treatment).
We note that the FDA’s approval was based on encouraging results from a phase III study (ML18147). Results from the study showed that patients continuing with an Avastin-based regimen, even after the worsening of their cancer, survived longer than those who underwent chemotherapy alone.
The risk of death for patients, who received Avastin plus standard chemotherapy as both the first- and second-line treatment of mCRC, was 19% lower in comparison to patients receiving chemotherapy alone.
Avastin is already approved by the FDA for treating patients suffering from mCRC in combination with intravenous 5FU-based chemotherapy. Roche has also gained approval for Avastin for treating patients, whose cancer worsened after chemotherapy alone.
Avastin plus fluoropyrimidine-based chemotherapy is approved in the EU for the treatment of adults suffering from metastatic carcinoma of the colon or rectum.
Roche carries a Zacks Rank #3 (Hold). However, other large cap pharma stocks, such as Bayer ( ( BAYRY - Analyst Report ) ), Novo Nordisk ( ( NVO - Analyst Report ) ) and Eli Lilly and Company ( ( LLY - Analyst Report ) ) currently look more attractive with a Zacks Rank #2 (Buy).

Read the full on RHHBY

Read the full Analyst Report on BAYRY

Read the full Analyst Report on LLY

Read the full Analyst Report on NVO

Email Print Share Rate Pos Rate Neg

Disclosure / Disclaimer Link
Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.
Quick Links

Services

My Account

Resources

Client Support

Follow Us

Facebook

Twitter

Linkedin

RSS

You Tube

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.

Copyright 2013 Zacks Investment Research

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.

Visit performance for information about the performance numbers displayed above.

NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.